

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
7 July 2016 (07.07.2016)



(10) International Publication Number
WO 2016/109480 A8

(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 9/00* (2006.01)
A61K 31/53 (2006.01) *A61P 9/10* (2006.01)
A61P 35/00 (2006.01) *A61P 31/04* (2006.01)
A61P 25/28 (2006.01) *A61P 31/12* (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2015/067781

(22) International Filing Date:

29 December 2015 (29.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/098,145 30 December 2014 (30.12.2014) US

(71) Applicant: **FORMA THERAPEUTICS, INC.** [US/US];
500 Arsenal Street, Suite 100, Watertown, Massachusetts
02472 (US).

(72) Inventors: **IOANNIDIS, Stephanos**; 8 Penobscot Road,
Natick, Massachusetts 01760 (US). **TALBOT, Adam
Charles**; 3 Hart Landing, Guilford, Connecticut 06437
(US). **FOLLOWS, Bruce**; 25 Baldwin Hill Rd, Littleton,
Massachusetts 01460 (US). **BUCKMELTER, Alexandre
Joseph**; 139 Prospect Street #5, Acton, Massachusetts
01720 (US). **WANG, Minghua**; 30 Squirrel Hill, Acton,
Massachusetts 01720 (US). **CAMPBELL, Ann-Marie**;
248 Webb Circle, Monroe, Connecticut 06468 (US).

(74) Agents: **FARMER, Dean** et al.; Cooley LLP, 1299
Pennsylvania Avenue, Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:


— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

27 October 2016

[Continued on next page]

(54) Title: PYRROLOTRIAZINONE AND IMIDASOTRIAZINONE DERIVATIVES AS OBIQUITIN-SPECIFIC PROTEASE 7 CUSP?) INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER USP7 MEDIATED DISEASES



(57) Abstract: The invention relates to pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one and imidazo[5,1-f][1,2,4]triazin-4(3H)-one derivatives as inhibitors of the ubiquitin-specific protease 7 (USP7) useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula (I) where R₁, R₂, R₃, R₄, R₅, R₅', R₆, X₁, X₂, m, and n are described herein.



(15) Information about Correction:
see Notice of 27 October 2016